HF
LYEL icon

HRT Financial’s Lyell Immunopharma LYEL Stock Holding History

HRT Financial’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$513K Buy
+36,575
New +$662K ﹤0.01% 2655
2024
Q4 		– Sell
-28,451
Closed -$785K – 2903
2024
Q3 		$785K Buy
+28,451
New +$836K ﹤0.01% 1368
2024
Q1 		– Sell
-24,835
Closed -$963K – 2758
2023
Q4 		$963K Buy
+24,835
New +$894K 0.01% 1005
2022
Q1 		– Sell
-11,122
Closed -$1.72M – 3531
2021
Q4 		$1.72M Buy
+11,122
New +$2.48M 0.01% 746

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

HRT Financial's LYEL Position: Q2 2026 in Review

HRT Financial opened a new position in Lyell Immunopharma (LYEL) in Q2 2026: 36,575 shares worth $513K. The stake represents ﹤0.01% of the portfolio and ranks #2655 among its holdings. This is a return to the name: HRT Financial previously reported a position in LYEL as recently as Q3 2024.

HRT Financial first reported a position in LYEL in Q4 2021 and has held it in 4 quarters since. The position peaked at $1.72M in Q4 2021. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • HRT Financial held 36,575 shares of Lyell Immunopharma worth $513K as of Q2 2026.
  • Lyell Immunopharma was a new HRT Financial position in Q2 2026.
  • Lyell Immunopharma made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #2655 holding.
  • HRT Financial first reported a position in Lyell Immunopharma in Q4 2021 and has held it in 4 quarters since.
  • HRT Financial's Lyell Immunopharma position peaked at $1.72M in Q4 2021.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.